ABF developed a novel method for the quantification of 3-hydroxybenzo[a]pyrene (3-OH-BaP) in urine, a metabolite of Benzo[a]pyrene.
Benzo[a]pyrene is classified as carcinogenic to humans (class 1) by the IARC (International Agency for Research on Cancer). It is formed during incomplete combustion or pyrolysis of organic materials. High levels are found in smokers and employees exposed in specific industrial settings: e.g. coke production, steel works, road construction, etc.
3-OH-BaP is formed by metabolic hydroxylation of benzo[a]pyrene and excreted in urine after glucuronidation. Our powerful LC-MS/MS method is able to detect 3-OH-BaP at trace levels down to 50 fg/ml in epidemiological and clinical trials with high sample numbers. Method validation according to FDA guidelines proved its unique sensitivity in combination with high precision and accuracy. So far, the assay was run for hundreds of samples of a clinical trial proving its extraordinary robustness.
This bioanalytical assay can be run under GLP conditions or according to ISO 17025 for clinical and preclinical study samples.
Contact us to receive a quote!
Nov 5th, 2015